Project description
Tackling the grand challenge of neurodegenerative diseases
With the ageing of the world population, the incidence of neurodegenerative diseases is on the rise. Affecting nearly 47 million people worldwide, these diseases remain difficult to treat. Characterised by a large variability in their origins, mechanisms and clinical expression, deciphering this variability is one of the biggest challenges in the treatment. The way forward is precision medicine, supported by highly personalised approaches for the greatest benefit of the patients. In this context, the EU joint programme initiative under JPCOFUND2 is a call for multinational research projects on personalised medicine for neurodegenerative diseases. The aim of the actions is to achieve the highest impact for the patients, their caregivers and society as a whole.
Objective
Worldwide, nearly 47 million people are currently estimated to be living with dementia, and the number is expected to almost double every 20 years, yet treatments that prevent or stop the progression of neurodegeneration are still lacking. Tackling this grand challenge requires enhanced coordination of national efforts to accelerate discovery. Such synergies have been created among 30 countries in the pilot EU JPI on Neurodegenerative Disease Research (JPND). JPND has a long standing experience in collaborative actions; since 2011, a cumulated funding of 132M€ has been dedicated to competitive transnational calls and JPND is now a reference for European and global knowledge and as an innovation platform in the area of neurodegenerative diseases. Building on earlier successes of the JPND Research Strategy in scaling-up and establishing synergies with Horizon 2020, there is a need to continue previous efforts to consolidate the JPND successes in defragmentation, better coordination and alignment amongst the countries, by developing new links with the EC. JPcofuND 2 aims at launching in 2019 an ambitious call for proposals on personalised medicine, where the benefits for the patients affected with neurodegenerative diseases will be explored through personalised diagnosis, personalised prevention and personalised care. Participating countries have earmarked 24,7 M€ of national funds for this call. Moreover, to expand the impact of the project, JPND will continue to implement other actions without EU co-funding such as aligning national research strategies, making databases more accessible and interoperable, developing enabling capacities such as supportive infrastructure and platforms, capacity building, education and training. These actions are required in parallel to achieve the highest impact for the patients, their carers and for society as whole and address this grand challenge in the coming years.
Fields of science
Keywords
Programme(s)
Funding Scheme
ERA-NET-Cofund - ERA-NET CofundCoordinator
75654 Paris
France
See on map
Participants (32)
00531 Helsinki
See on map
75013 Paris
See on map
K1T 4H8 Ottawa Ontario
See on map
9101002 Jerusalem
See on map
51147 Koln
See on map
75013 Paris
See on map
1249 074 Lisboa
See on map
1090 Wien
See on map
4365 Esch-Sur-Alzette
See on map
9500-094 Ponta Delgada
See on map
1000 Bruxelles / Brussel
See on map
1000 Bruxelles / Brussel
See on map
D02 H638 Dublin
See on map
1100 Kobenhavn K
See on map
28029 Madrid
See on map
118 12 Prague
See on map
Participation ended
00153 Roma
See on map
Participation ended
1000 Ljubljana
See on map
00144 Roma
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
20133 Milano
See on map
SN2 1FL Swindon
See on map
30 312 Krakow
See on map
1077 Budapest
See on map
0283 Oslo
See on map
3012 Bern
See on map
101 38 Stockholm
See on map
06100 Ankara
See on map
Participation ended
1050 Riga
See on map
2593 CE DEN HAAG
See on map
00153 Roma
See on map
LV-1050 RIGA
See on map
1000 Ljubljana
See on map